Key result
Simvastatin lowers cholesterol more than pravastatin in beta-cells but causes greater cytotoxicity and insulin suppression.
Why the study?
Does simvastatin compared to pravastatin affect intracellular cholesterol, cytotoxicity, and insulin secretion in a fatty acid-challenged mouse insulinoma MIN6 β-cell model?
Does simvastatin compared to pravastatin affect intracellular cholesterol, cytotoxicity, and insulin secretion in a fatty acid-challenged mouse insulinoma MIN6 β-cell model?
Answers are grounded in this paper and cite their sources.
In a fatty acid-challenged β-cell model, simvastatin was more effective at lowering cholesterol but more cytotoxic and suppressive of insulin secretion than pravastatin, though the insulin suppression was reversible.
Introduction Familial hypercholesterolemia, the highly prevalent form of dyslipidemia, is a well-known risk factor for premature heart disease and stroke worldwide. Statins, which inhibit 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase, are the first-choice treatment for dyslipidemias, and have been effective in reducing the risk of stroke and myocardial infarction. However, emerging evidence indicates that statins may increase the incidence of new-onset type 2 diabetes by reducing β-cell mass and function. Notably, past in vitro reports studying the effects of statins on β-cells were performed without including free fatty acids in the model. This factor should have been addressed since these agents are used to treat individuals with hyperlipidemia. Methods Here, we used a mouse insulinoma MIN6 β-cell culture model to assess the efficacy, cytotoxicity, and insulin-suppressive effects of simvastatin and pravastatin in the presence of palmitic, linoleic, and oleic acids cocktail to mimic mixed lipids challenge in a biologically relevant setting. Results and discussion Our findings indicate that simvastatin was more effective in lowering intracellular cholesterol but was more cytotoxic as compared to pravastatin. Similarly, simvastatin exhibited a higher suppression of total insulin content and insulin secretion. Both drugs suppressed insulin secretion in phases 1 and 2, dose-dependently. No significant effect was observed on mitochondrial respiration. More importantly, elution experiments showed that insulin content diminution by simvastatin treatment was reversible, while exogenous mevalonate did not improve total insulin content. This suggests that simvastatin's influence on insulin content is independent of its specific inhibitory action on HMG-CoA reductase. In conclusion, our study identified that simvastatin was more effective in lowering intracellular cholesterol, albeit it was more toxic and suppressive of β-cells function. Notably, this suppression was found to be reversible.
No takes yet. Share an insight, caveat, or question.
Arefanian et al. (2024) studied Hyperlipidemia / Statin-induced β-cell toxicity. Simvastatin vs. Pravastatin was evaluated on Efficacy, cytotoxicity, and insulin-suppressive effects. In a mouse β-cell model, simvastatin was more effective in lowering intracellular cholesterol but more cytotoxic and suppressive of insulin content and secretion compared to pravastatin.
Synapse has enriched 10 related papers. Consider them for comparative context: